Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Virbac launches new anaesthetic product Buprevet

Virbac launches new anaesthetic product Buprevet

5th November 2014

Virbac has announced the launch of Buprevet, buprenorphine-based, injectable solution for anaesthetic applications.

It is indicated for the potentiation of sedative effects of centrally-acting agents in dogs, as well as for use in both cats and dogs as part of a multimodal approach to analgesia. Buprevet joins brands such as Medetor, Revertor and Vetflurane in the company's anaesthetic range.

Buprevet's potentiation effects ensure less sedation is needed in the pre-medication and anaesthetisation of animals, facilitating smoother recoveries with more comfortable patients.

Moreover, the ten ml multi-dose bottle offers additional flexibility to practices, as the vial can be broached up to 25 times and can be left open for up to 28 days.

Sarah Walker, product manager at Virbac, said: "Buprenorphine is a potent, high-affinity, synthetic opioid agonist which forms a key element of practice anaesthetic protocols and complements our existing anaesthetic range."

Virbac is the leading dedicated veterinary pharmaceutical company in the world, offering a wide range of award-winning products for both large and small animals.ADNFCR-8000103-ID-801758678-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.